BioSpace / Business Wire · Jun 2026
FDA granted Orphan Drug and Rare Pediatric Disease designations to GEn-1123 for Duchenne muscular dystrophy, a regulatory milestone that supports the company’s rare-disease program.
AI platform accelerating therapies for rare & inflammatory diseases.
Company research
Public company, workplace, funding, and market signals
Overview
GEn1E Lifesciences is a clinical-stage, Phase 2 biotech developing AI-guided precision immunomodulators for inflammatory and rare diseases. Its lead asset is GEn-1124, a p38α:MK2 dual signal modulator for ARDS; the company also pursues GEn-1123 for rare chronic indications and an ERK 1/2 program. Public sources vary on the founding year (2018 on the company site/Y Combinator vs. 2019 on LinkedIn), so 2018 is used here.
Primary product
GEn-1124, a p38α:MK2 dual signal modulator for acute respiratory distress syndrome (ARDS) and other inflammatory indications
Founded
2018
Headquarters
Palo Alto, California, USA
Team size
10-20
Industry
Biotechnology Research
Sub-industry
Clinical-stage AI-enabled drug discovery and immunomodulatory therapeutics
Offices
Palo Alto, California, USA
Mountain View, California, USA
Baltimore, Maryland, USA
Business model
Clinical-stage therapeutic development
AI-enabled platform partnerships
Drug discovery/licensing collaborations
Funding
Stage
Series A
Total raised
$22.5M
Latest round
Corporate Minority · Oct 2025
Latest amount
$5.5M
People & investors
Leadership
CEO, Founder, and Board Director
Chairman of the Board
Head of Clinical Operations
Head of Business Development, Japan
Co-founder, AI/ML Platform, and Board Director
Founders
Co-Founder, COO, and GC
Work & culture
Mission-driven, fast-moving, multidisciplinary biotech team emphasizing speed, capital efficiency, precision medicine, and close collaboration across AI/ML, clinical, toxicology, and translational science functions.
Compensation
No company-published salary bands were found. Third-party estimates suggest average compensation around $119k/year in the U.S., with typical ranges roughly from $105k to $135k depending on role.
Benefits
401(k)
time off / PTO
Product & market
Pricing
Not publicly disclosed; appears to be a B2B biotech model driven by therapeutics development and strategic partnerships.
Differentiators
- —Selective dual signal modulation that inhibits MK2 while sparing anti-inflammatory MSK1/2 signaling
- —Allosteric binding to a novel p38α site rather than traditional ATP-pocket inhibition
- —AI-driven GRID platform spanning discovery through clinical development
- —Fast progression from discovery to Phase 2 in about 2.5 years using seed capital
- —Clinical and biomarker-guided development with multi-omics and patient endotyping
Technology
GRID AI platform
machine learning
neural networks
gradient boosting
hidden Markov models
multi-omics
patient endotyping
curated public and proprietary datasets
RNA-seq gene expression profiling
Olink proteomics
allosteric binding / novel binding pockets
Competitors
Insitro
BridgeBio
BeiGene
Jazz Pharmaceuticals
Deep Genomics
Noetik
Scale & contact
Estimated revenue
Approximately $1M-$3M in annual revenue, based on third-party estimates
Estimated monthly visits
2.2K
Traffic estimate as of May 2024
Latest news
Business Wire · Apr 2026
GEn1E entered a strategic partnership with Rubicon Research to use its GRID AI platform for patient stratification while accessing Rubicon’s formulation, manufacturing, and commercialization capabilities.
UM Ventures · Sep 2025
UM Ventures announced a Series Seedplus investment in GEn1E, saying the company had raised over $21M in seed investment and was progressing a Phase 2 ARDS program.
GlobeNewswire · Dec 2024
GEn1E appointed François Nader as chair of the board, strengthening its governance and life-sciences leadership bench.
GlobeNewswire · Oct 2024
The company announced JPET publication of a landmark study describing the mechanism of its p38α:MK2 dual signal modulator platform.
Jobs and careers at GEn1E Lifesciences
0 jobs at GEn1E Lifesciences
No open positions
Check back later for new openings